- Feb. 7, 2019
-- LGM Pharma, an innovation-driven active pharmaceutical ingredient (API) company, headquartered in Erlanger, Kentucky with offices in Florida, New Jersey and Israel recently announced the appointment of Hamilton J. Lenox as Senior Vice President of Business Development at the Boca Raton, Florida location. In this capacity, Mr. Lenox will be responsible for leading LGM's drug development unit's sales, business development and marketing team.
Mr. Lenox has more than 17 years' experience in drug development, having represented CDMOs in the US, Europe, China and India, and he brings significant expertise and experience in the small molecule, biologic, peptide, oligonucleotide and personalized vaccine drug development markets to LGM. He most recently led CPC Scientific's East Coast business development team, strengthening their clinical and commercial stage peptide therapeutic pipeline while also helping develop their new service offering supporting peptide based neoantigen programs. Prior to that he directed small molecule and oligonucleotide business development efforts at Nitto Denko Avecia, revitalizing their struggling small molecule facility while also increasing Avecia's oligonucleotide pipeline for the East Coast and Asian markets. He holds a BS in Chemistry from DePaul University, a MS in Biochemistry from Northwestern University and an MBA from Florida International University.
According to Mendy Schurder, COO for LGM, "We are excited to have Hamilton as part of the team. He has a proven record of facilitating long-term business relationships with both customers and industry luminaries. His extensive experience assisting biotech and pharma organizations during the drug development lifecycle, combined with his strong network, are assets that will complement and enhance LGM's ability to meet the needs of our customers as we continue to provide quality, innovative products to the marketplace."
For more information visit http://www.lgmpharma.com